Page 27 - Shimadzu Journal vol.9 Issue1

Clinical Research

drugs, such as nafamostat (an anticoagulant). While the develop-
ment of products containing multiple drugs in a single dosage form
is also expected, in this second application, analytical conditions
were explored for quantitative analysis of just favipiravir.

Analysis of Favipiravir in
Human Plasma

Analysis of Favipiravir in Human
Plasma Using Fully Automated Sample
Preparation LC/MS/MS System

Envisioning that hospitals will use a single analytical system
(LC-MS/MS) for multiple investigations, the applications utilized
the same type of column and other analytical conditions when-
ever possible.
In addition, when creating a quantitative analysis method that
includes LC-MS/MS, a deproteinization pretreatment step is es-
sential for measuring drug concentration levels in blood. To meet
customers’ needs, for each application in this article, both manual
and automated sample pretreatment methods were used.

This article also describes an HPLC-based quantitative analysis
method for favipiravir that uses manual sample pretreatment and a
fluorescence detector to detect concentrations in the µg/mL range.

Quantitative Analysis of Favipiravir
Spiked in Plasma Using by HPLC

Learn more about the latest application.
Fully automated quantification of Meropenem,
Tazobactam, Piperacillin and Dexamethasone in plasma

Learn more about Shimadzu’s response
to the COVID-19 pandemic
https://www.shimadzu.com/covid-19/

Shimadzu Journal vol.9 Issue1 26